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Amyloid-β  in the cerebrospinal f luid of APP transgenic mice does not 
































Abeta 40 and sAPP levels were measured using Human 6E10 and APPalpha/sAPPbeta Kits 










App23	 tg	CSF	 18	 14	
App23	 tg	CSF	 24	 14	
App23	 tg	CSF	 24	 14	
App23	 tg	CSF	 24	 14	
App23	 tg	CSF	 18	 21	
App23	 tg	CSF	 18	 21	
App23	 tg	CSF	 24	 21	
App23	 tg	CSF	 24	 21	
App23	 tg	CSF	 24	 21	
App23	 wt	CSF	 3	 21	
App23	 wt	CSF	 24	 21	
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App23	 FB	 24	 20	
App23	 FB	 24	 20	
C57BL6	 tg	CSF	 24	 21	
C57BL6	 tg	CSF	 18	 21	
C57BL6	 tg	CSF	 18	 21	
App23	 conc.	tg	CSF	 24	 11	
App23	 conc.	wt	CSF	 24	 11	












Sample	 Aβ40,	pg/μl	CSF	 sAPPα,	pg/μl	CSF	 sAPPβ,	pg/μl	CSF	
APP23	CSF	 4.2	 92	 121	













APP23	 tg	CSF	 14	 4	 0.77	 0.94	 1.15	 0.56	
APP23	 tg	CSF	 21	 5	 0.79	 0.91	 1.05	 0.19	
APP23	 wt	CSF	 21	 3	 0.65	 0.81	 1.01	 0.06	
APP23	 FB	 20	 2	 0.41	 0.54	 0.70	 0.00***	
C57BL6	 tg	CSF	 21	 3	 0.00	 0.00	 0.00	 NA	
APP23	 conc.	tg	CSF	 11	 1	 0.59	 0.88	 1.30	 0.52	
APP23	 conc.	wt	CSF	 11	 1	 0.72	 1.10	 1.67	 0.66	
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Tau is a microtubule stabilizing protein that forms aggregates in many neurodegenerative 
diseases named tauopathies, including Alzheimer’s disease (AD). It was shown that tau 
derived from tauopathy patient brains could induce local protein aggregation in a prion-like 
manner when injected into susceptible mice models. At the same time, increase of tau levels 
in the cerebrospinal fluid (CSF) of AD patients correlates with severity of the disease. 
However, a reliable presymptomatic marker in AD is currently unavailable. A potential prion 
like property of tau in the CSF could have a possible diagnostic application. 
Here we investigated the seed-like potential of tau present in the CSF of mice carrying a tau 
mutation (P301S). We collected CSF from aged, tangle bearing P301S mice and injected it 
into young, pretangle staged P301S mice. As a result, we observed significantly higher 
number of pathologically hyperphosphorylated, AT8 positive NFTs in mice treated with CSF 
from P301S mice. Increased tau pathology was noted anterior and posterior to the 
inoculation site, as well as in the contralateral hippocampus. This suggests that CSF tau can 
exhibit seed like properties in vivo, and can induce tau hyperphosphorylation and fibrillization 
that is transmitted along existing anatomical networks. This knowledge could be useful in the 






Tau is a natively unfolded protein that promotes microtubules stability in neuronal cells. 
However, in pathological conditions, it becomes hyperphosphorylated, it oligomerizes, 
fibrillates and eventually forms intracellular aggregates. This is characteristic of Alzheimer’s 
disease (AD), but also other neurodegenerative disorders known as tauopathies, including 
progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal 
dementia (FTD) (Goedert et al. 2010; Mandelkow & Mandelkow 2011; Jucker & Walker 
2013a). In AD patients tau propagates from one brain region to another in a specific pattern 
during the course of the disease (Braak & Braak 1997). Moreover, the injection of brain 
extracts from human P301S tau transgenic mice into wild type human tau transgenic mice 
induces aggregation of the wild type human tau (Clavaguera et al. 2009), suggesting that tau 
aggregation can be transmitted in a prion-like manner. In a number of subsequent studies, 
injection of recombinant tau fibrils or patients’ derived brain extracts containing aggregated 
tau caused formation of neuro fibrillary tangles (NFTs) that propagated from the injection site 
to connected brain regions in a stereotypic and time dependent manner (Liu et al. 2012; de 
Calignon et al. 2012; Clavaguera et al. 2013; Iba et al. 2013; Ahmed et al. 2014). This suggests 
that a pathological conformation or aggregation state of tau can be locally induced by an 
inoculated seed, followed by transneuronal spreading in a way similar to prions (Frost & 
Diamond 2009; Jucker & Walker 2011; Clavaguera et al. 2014). In this light, it has been shown 
that tau aggregates can transfer between cells and might be present in the extracellular 
space (Frost & Diamond 2009; Yanamandra et al. 2013; Pooler et al. 2014).  
Tau is physiologically present in the cerebrospinal fluid (CSF). However, it has remained 
unexplored whether tau in the CSF is soluble, forms oligomers, and/or fibrillizes. CSF 
concentrations of tau and phosphorylated tau are being used for clinical diagnosis of AD, in 
conjunction with CSF amyloid-β levels, cognitive tests, and various forms of brain imaging. 
Increased tau levels in CSF correlate best with cognitive decline in AD patients (Blennow et al. 
1995; Wallin et al. 2006; Blennow et al. 2015). However, most of those markers are 
associated with disease onset, and reliable early, presymptomatic markers, that might 
predict the conversion of mild cognitive impairment to AD, are still missing (Blennow et al. 
34	
	
2010b; Blennow et al. 2014). Detection of pathologically conformed tau species in CSF might 
thus be serving as an early diagnostic marker in AD and other tauopathies.  
In order to study the presence of seeding competent tau species in CSF, we here inoculated 
CSF derived from tau transgenic mice into susceptible host mice. CSF was collected from 
P301S mice that carry a tau mutation typical of a familial form of FTD (Allen et al. 2002), and 
injected intrahippocampally into young mice of the same strain. P301S develop NFTs 
progressively with age while their level of CSF tau increases (Yamada et al. 2011). Unilateral 
injection of CSF collected from aged, tangle bearing P301S mice into pre-tangle staged P301S 
mice increased the number of NFTs in both the injected and non-injected hippocampus, as 
compared to littermates inoculated with non-transgenic murine CSF. This data suggests that 
seeding competent tau species with prion-like potential reach the CSF compartment in P301S 
mice. Given the easy accessibility of CSF in human patients, the detection of prionoid tau 






Materials and Methods 
 
Mice 
We used homozygous tau transgenic mice expressing the shortest human four-repeat tau 
isoform containing the P301S mutation under the thy1.2 promoter (P301S mice) (Allen et al. 
2002), and aged matched, non-transgenic C57BL/6 control mice. Animal experiments were 
performed in compliance with protocols approved by the official local Committee for Animal 
Care and Animal Use of the Canton of Basel. 
 
Murine CSF collection 
CSF was collected by puncturing the cisterna magna after deeply anesthetizing the animals, 
as previously described (Skachokova et al. 2015). Next, it was spun down at 2500 rpm for 2 
min and the supernatant was collected and immediately frozen. Visibly blood contaminated 
CSF was discarded.  
CSF processing 
Freshly collected human CSF was spun down at 3000 rpm for 2 min to separate cell debris. 
The supernatant was collected and frozen at −80° C. Next it was pooled and concentrated by 
lyophilization (−80° C, 0.01 mbar vacuum pressure, for 24 hours) and reconstituted in sterile 
H2O. The final concentration was measured by ELISA (see Fig. S6). 
 
Stereotaxic surgery 
Three months-old P301S mice and non-transgenic C57BL/6 control mice were anaesthetized 
with a mixture of ketamine (10 mg/kg) and xylazine (20 mg/kg) and placed on a heating pad 
to maintain body temperature during surgery. Mice were injected in the right (R) 
hippocampus (A/P, −2.5 mm from bregma; L, − 2.0 mm; D/V, −1.8 mm) using a Hamilton 
syringe, as previously reported (Clavaguera et al. 2009). Each received a unilateral stereotaxic 
injection of 5 μl concentrated CSF, at a speed of 1.25 μl/min. Following the injection, the 
needle was kept in place for additional 3 minutes before withdrawal. The surgical area was 
cleaned with sterile saline and the incision sutured. Mice were monitored until recovery from 
anaesthesia and checked regularly following surgery. For number of mice used and injected 





Following 4 months seeding time, mice were deeply anaesthetized with pentobarbital (100 
mg/kg) and killed by transcardial perfusion with 20 ml cold PBS, followed by 20 ml 4% 
paraformaldehyde in PBS. The brains were dissected and post-fixed overnight. Following 
paraffin embedding, 5 μm coronal sections were prepared. Sections were silver-impregnated 
following the method of Gallyas-Braak to visualize filamentous tau pathology (Gallyas 1971; 
Braak et al. 1988). Haematoxylin and eosin staining was performed for morphological 
analysis. For immunohistochemistry, the following anti-tau antibodies were used: AT8 and 
AT100 (both 1:1000, Thermo Scientific), with secondary antibodies from Vector Laboratories, 
Burlingame, CA (Vectastain ABC kit), as previously described (Ozcelik et al. 2013; Ozcelik et al. 
2016). 
 
Quantification and statistical analysis 
For quantification, on average 7-9 sections per mouse (sections with bad quality were 
discarded) were analyzed at levels comprising the injection site (from -2 to -3 um from 
Bregma), and sections form the injected and non-injected hippocampal side were selected at 
corresponding levels. The number of silver stained tangles and AT8 and AT100 positive 
aggregates was counted using the Cell counter plugin in ImageJ. Then average score per 
group was made. For the AT8 heat map average tau pathology per Bregma level per group 
was calculated and manually color graded. The amounts of granular tau pathology in 3 
hippocampal regions (CA1, CA3, dentate gyrus) at varying Bregma levels were qualitatively 
assessed by two independent researchers and an average score was obtained. Brain images 
that were used and modified are from the Mouse Brain Atlas (Franklin and Paxinos, Elsevier 
2007). All group scores were compared using unpaired Student t-test. P values are reported 








Parallel to age increase, P301S mice develop hyperphosphorylated tau, later assembled into 
PHFs and NFTs, that is AT8, AT100 and Gallyas positive (Allen et al. 2002) (Fig. S2). In seeded 
mice, we quantified any change in their endogenous pathology based on those markers (Fig. 
1). Injections of CSF from tangle bearing P301S into young, pretangle P301S mice resulted 
into increased number of hyperphosphorylated tau, as compared to wild type CSF seeded 
mice (Fig.2 A, B). Moreover, this effect was present throughout the hippocampus and also 
bilaterally, in the non-injected hippocampal side (Fig.2 E). Also, when we looked at sections 
anterior/around the injection side, we found significant differences between the P301S CSF 
and BL6 CSF injected hippocampi, and also between same groups non-injected sides (Fig.2 A, 
B; p<0.05). This indicates that hyperphosphorylated tau pathology can be transmitted and 
induced via CSF derived from mutated tau expressing mice. 
 
 
F igure 1.  P301S mice normally develop hyperphosphorylated tau positive for AT8 and AT100 antibodies, and 
Gallyas silver stained NFTs in both hippocampi. The magnified immunohistochemical images show cells of the 
CA3 region in the right hippocampus.  
 
Injection of P301S brainstem homogenate (BS) resulted in a higher number of AT8 positive 
neurons in both hippocampal sides, as compared to BL6 BS injections, that was significant in 
the left hippocampus and showed a trend in the right (Fig.2 F). When we focused on sections 
anterior/close to the injection site, we found significant increase in the number of 
hyperphosphorylated tau in both injected and non-injected P301S BS seeding hippocampi, as 
compared to BL6 BS seeded (Fig. 2 C, D, p<0.05 for R and p<0.001 for L). Finally, injection 
with P301S CSF resulted in an effect similar to the P310S brain stem homogenate, even 
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though total tau/ phospho-tau concentrations in the first one are more than a thousand 












Next, we analyzed the AT8 pathology in the CSF seeded mice on different anatomical levels 
and hippocampal subregions. We found a significant effect anterior and in proximity to the 
injection site, specifically in the CA1 and DG regions between the injected hippocampus of 
P301S and BL6 CSF seeded mice (Fig. 3 A, B). Furthermore, in P301S CSF seeded mice we 
found a tendency for higher amount of hyperphosphorilated tau in the injected hippocampus 
CA3 region, versus the contralateral one. When analyzing AT8 load posterior to the injection 
site, we saw significant increase of AT8 positive hyperphosphorylated tau in both the CA1 and 
DG of the injected and non-injected hippocampus in P301S seeded mice (Fig. 3 A, C). This 
shows that injection of mutated tau containing CSF induced a local seeding effect after 4 
months time that was spread throughout the hippocampus based on existing anatomical 
connections. 
 
F igure 3.  Quantification of hyperphosphorylated tau pathology in murine CSF seeded mice in different 
subhippocampal regions. Number of AT8 positive neurons in the CA1, CA3 (incl. CA2) and DG in P301S CSF (n=5) 
and BL6 CSF (n=5) seeded mice is presented as a heat map anterior (comprising sections at -2 to -2.5 from 
Bregma) and posterior (-2.6 to -3 from Bregma) to the injection site (A). Scale bar depicts AT8 load. Number of 
AT8 positive tau is presented as an average value from all sections anterior (B) and posterior to the injection site 




Quantification of AT100 pathology, a later marker of tau hyperphosphorylation (Augustinack 
et al. 2002), also resulted in a significant increase as a result of P301S CSF seeding, as 
compared to BL6 CSF treatment, as seen in the injected hippocampus (Fig.3 A). At the same 
time, there was no significant difference in the amount of Gallyas positive tangles in the right 
hippocampus between P301S and BL6 CSF seeded mice (Fig.3 B), or for BS seeded mice (Fig.3 
C). Thus, our injections induced an increase of endogenous tau hyperphosphorylation and 
formation of prefibrillar tau, but not of late stage Gallyas positive NFTs, in P301S host mice. 
This may be due to the limited seeding time, restricted by the life span of homozygous P301S 
mice due to their progressive motor symptoms (Allen et al. 2002).  
 
 
F igure 4.  Quantification of tau pathology in the injected right hippocampus between conc. P301S CSF (n=5) 
and conc. BL6 CSF (n=5) seeded mice as based on AT100 antibody (A), or Gallyas silver staining (B). The number 
of Gallyas positive NFTs in brain stem seeded mice (P301S BS n=6, BL6 BS n=5) was also analyzed (C). * indicates 








We recently showed that CSF derived amyloid-beta lacks prion-like potential (Skachokova et 
al. 2015; Fritschi et al. 2014). In the present study, we investigated the prion-like potential of 
tau protein present in the CSF of tau transgenic mice and compared it to that in wild type-
mice CSF.  
Induction of tau propagation along synaptically connected regions using brain homogenates 
has been previously reported in P301S mice (Ahmed et al. 2014; Boluda et al. 2014). In order 
to see whether also CSF harbors seeding competent tau species, we here collected CSF from 
aged, tangle bearing P301S mice and injected it into young, pre-tangle staged P301S mice. 
Tau pathology was assessed and compared to littermate mice inoculated with non-transgenic 
mouse CSF. As a result, we observed significantly higher hyperphosphorylated, AT8 positive 
tau, a marker of prefibrilar tau pathology, throughout the hippocampus in mice treated with 
CSF from aged P301S mice. In addition, the observed pathology was present bilaterally in the 
contralateral hippocampus, and also in anterior and posterior directions, and not only 
localized to the injection site. This suggests that mouse CSF tau can exhibit seed like 
properties in vivo, and tau hyperphosphorylation could be induced and transmitted based on 
synaptic connections. These are the first evidences that CSF tau could exhibit prion-like 
characteristics.  
As a result of CSF seeding we observed increased AT8 and AT100 positive structures as 
indicators of pathological, hyperphosphorylated tau (Allen et al. 2002), but no increase in the 
number of late, Gallyas positive NFTs. Tau hyperphosphorylation is an early marker of AD, 
characteristic of the preclinical phase, and precedes tau aggregation by decades in human 
sporadic AD cases (Braak & Del Tredici 2015). It may be the case that because of the limited 
seeding time, an increase in Gallyas positive NFTs was not apparent in our P30S mice, or 
simply CSF tau causes the hyperphoshorylation, but not aggregation of endogenous tau. In 
addition, seeding of AD brain in P301S mice for 3 months increased AT8 signal in the CA3 
region of the injected hippocampus, versus the non-injected one, and tau propagation 
happened in a timely and connectivity based manner (Boluda et al. 2014). These findings are 
similar to our P301S CSF seeding results, however, we also note an increase in other 
hippocamapal subregions as the CA1 and DG that may be due to the variation in the injection 
site and/or extended seeding time. In another study, injection of tau seeds into P301S hetero 
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mice for 6 months induced AT8 hyperphosphorylation in interconnected to the injection site 
regions, resulting in network dysfunction and memory impairment. Importantly, this was 
correlated with the presence of tau oligomers and tau hyperphosphorylation, rather than 
with fully mature NFTs (Stancu et al. 2015), implicating early pathological forms of tau as 
culprits of neuronal dysfunction. Furthermore, hyperphosphorylated tau in the CSF is best 
correlated with cognitive decline, as opposed to total tau (Braak et al. 2013). All this suggests 
that increase in AT8 positive tau per se, as seen in our model and previous studies, can be an 
indicator of both toxicity and seeding effect. 
Currently, it is not known how seeding competent tau reaches the CSF. Previously, it has 
been shown that tau propagates via synaptically connected regions, however the exact 
mechanisms are still unknown (Pooler et al. 2014; Clavaguera et al. 2015). Using an in vitro 
cell model it was demonstrated that phosphorylated tau is actively secreted via exosomal 
release, and also found in vesicles in AD patients CSF (Saman et al. 2012), as well as in 
exosomes isolated from P301S mouse brains (Asai et al. 2015). Furthermore, infusion of tau 
antibodies into tau transgenic mice lateral ventricles reduced tau seeding activity by reducing 
tau hyperphosphorylation and aggregation, implicating extacellular tau in AD pathology as 
seed responsible (Yanamandra et al. 2013). Based on these evidences and our results, it is 
possible that seeding prone tau is released by the neurons and reaches the CSF. In addition, 
we injected our mice with a mixture of P301S CSF and AT8 and AT100 antibodies to see 
whether this would inhibit the observed seeding effect (data pending).  
In conclusion, our results suggest the presence of prion-like tau in the CSF of P301S mice. 
This provides the basis for future studies using human patients CSF, and possibly opens a 
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Genotype	 Seed	 Seeding	time,	mo	 N	
P301S	 P301S	CSF	 4	 5	
P301S	 BL6	CSF	 4	 5	
P301S	 P301S	BS	 4	 6	
P301S	 BL6	BS	 4	 5	




























with	 Bl6	 CSF	 (A),	 P301S	 CSF	 (B),	 P301S	 BS	 (C),	 or	 BL6	 BS	 (D),	were	 evaluated	 at	 -2,	 -2.5	 and	 -2.9	mm	 from	
Bregma,	 corresponding	 to	 the	 left,	 central	 and	 right	 columns.	 Scores	were	made	 as	 based	 on	 average	 AT8	


































































































(a-c) Overview on the transgenic and co-transgenic mouse lines used for the present studies. Tau 
isoforms expressed are shown. Dark grey boxes indicate the tau repeat domains (3R or 4R isoforms), 
and light grey boxes N-terminal inserts (e.g. ALZ17 ≙ 2N4R).  
The tau cDNA constructs are either driven by a standard Thy1.2 minigene (Thy1.2) or by a modified 
Thy1.2 minigene that contains a tetracycline controlled transcriptional silencer element (Thy1.2-tTS) 
in case of the TAU62 mouse. (a) shows the tau isoforms expressed in single-transgenic lines. (b) 
shows the tau forms of 3 mouse lines co-expressing full-length tau with Δtau. (c) depicts 2 mouse 













TAU62 mice develop a slowly progressive motor phenotype. 
Motor fitness was assessed on a vertical mesh grid. Time spent on the grid progressively declined in 
TAU62 mice, while B6 controls were unimpaired at 12 months and showed a mild decline at 18 











(a) Extensive hyperphosphorylation of tau was seen in the brainstem of old homozygous P301S mice 
by staining with antibodies targeting late phospho-epitopes. Multiple tau tangles and granular 
aggregates were detectable in these mice by Gallyas silver stain. The scale bar in a corresponds to 
50 µm. (b) Western blotting under non-reducing conditions revealed high-molecular tau species in 
paralyzed P301SxTAU62on mice (lanes 6&7); similar tau species were seen in aged tangle bearing 
homozygous P301S mice (lane 5). When tau expression was halted, no more high-molecular tau 
forms were detectable in P301SxTAU62on-off mice (lane 3; Western blot performed with anti-tau 
antibody HT7). (c) Staining with the RD3 antibody targeting Asp421 shows the presence of Δtau in 
the high molecular weight tau species. (d) Sarkosyl-extraction detects only soluble tau species in 
paralyzed P301SxTAU62on mice (“sol”: sarkosyl-soluble tau; “insol”: sarkosyl-insoluble fraction). 
(e-g) Δtau was widely expressed in the spinal cord of P301SxTAU62on mice (e) and phosphorylated at 
the AT8 epitope (f). Upon cessation of Δtau expression, Δtau- and AT8-positive tau was no longer 










(a-m) P301SxTAU62 mice exhibit signs of Golgi disruption, protein missorting and mitochondrial 
clustering. These signs are reversible upon cessation of Δtau expression. Immunohistochemistry 
using antibodies against MG160 (a-f), synaptophysin (g-i), VAMP2 (k-m), and cytochrome C oxidase 
(COX) (n-p), in the hippocampus of non-transgenic mice (B6), 3-week-old paralyzed mice 
(P301SxTAU62on) and recovered mice 6 weeks after cessation of Δtau expression (P301SxTAU62on-
off). The scale bar in a corresponds to 19 µm in d-f, 63 µm in a-c and g-i, and 400 µm in k-m. The 









(a-c) Young TAU62 mice exhibit normal sciatic nerves (Masson’s trichrom stain (a); para-
Phenylenediamine (b); immunohistochemistry using 2f11 antibody  (c)). The scale bar in c 
corresponds to 30 µm in a-c.  
(d-g) M. gastrocnemius stained for ATPase (pH 4.2). Dark type 1 fibres (1) and light type 2 fibres (2). 
The scale bar in g corresponds to 50 µm (for d-g). P301S: heterozygous mice transgenic for human 
mutant P301S tau, aged 3 weeks; TAU62: heterozygous mice expressing 3R tau151-421, aged 3 weeks; 
P301SxTAU62on: paralyzed mice, aged 3 weeks; P301SxTAU62on-off: recovered mice, 6 weeks after 







(a-i) Co-expression of 3R wild-type tau and Δtau (ALZ31xTAU62 mice) causes paralysis and 
neuropathy, which are not reversed upon cessation of Δtau expression. (a) Paralyzed (aged 3 weeks) 
and non-recovered (3 weeks after cessation of Δtau expression) ALZ31xTAU62 mice (see also video 
S6). (b) Absence of recovery of motor function as assessed by a grid-test of ALZ31xTAU62 mice 
following the removal of doxycycline between 14 and 16 days (blue line; triangles indicate the times of 
euthanasia, n=6). Motor function of heterozygous ALZ31 mice (green line, n=7). (c) Western blot with 
HT7 of brainstem tissue from non-transgenic mice (B6), TAU62 mice, ALZ31 mice and ALZ31xTAU62 
mice. Actin staining was used as the loading control. (d-i) Histological analysis of paralyzed 
ALZ31xTAU62 mice aged 3 weeks, using AT8 (d), AT100 (e), NF200 (f), Holmes-Luxol (HL) (g), 
Masson’s trichrome (h), and Hematoxylin-eosin (HE) stainings (i). The arrow in (g) points to a 











(a,b) Robust expression of the two full-length tau isoforms in P301SxALZ31 (a) and ALZ17xALZ31 (b) 
co-transgenic mice. For comparison, expression of mice co-transgenic for Δtau with full-length tau, as 
well as the respective single transgenic mice is shown. Western blots run under reducing conditions 





Supplemental Experimental Procedures 
 
Antibodies used for immunohistochemistry (IHC) and Western blotting (WB) 
(species is mouse, unless indicated otherwise):  
 
 
Antibody Target Dilution Source 




Pierce, Rockford, IL  
#MN1000 
BR134 human tau WB 1:1000 (1) 
Tau-C3 Tau cleaved at 
residue Asp421  
WB 1:1000 
IHC 1:1000 
















Peter Davies, Albert Einstein College of 
Medecine, Bronx, NY 
MC1 Tau 
aa 5-15, 312-322  
IHC 1:100 Peter Davies, Albert Einstein College of 
Medecine, Bronx, NY 
2F11 neurofilament (NF) 
NF-L, NF-H (70kD) 
IHC 1:800 Dako, Glostrup, DK  
#M0762 
NF200 neurofilament (200kD) IHC 1:100 (2) 
GFAP glial fibrillary acidic 
protein 
IHC 1:500 Thermo Fisher Scientific Inc., Kalamazoo, 
MI      
#MS-1407-R7 
Synaptophysin synaptophysin IHC 1:1000 Millipore Corporation, Billerica, MA 
#MAB5258 
MG160 (rabbit) Golgi apparatus IHC 1:1000 Nicholas Gonatas, Pathology and 




transport vesicles IHC 1:1000 Synaptic system, Goettingen, Germany  
# 104 202 
GAPDH (6C5) GAPDH WB 1:1000 Santa Cruz Biotechnology, Santa Cruz, 
CA, #32233 
ß-actin actin WB 1:5000 Sigma-Aldrich, Saint Louis, MO #A5316 
Cox subunit 1a mitochondrial 
staining 
IHC 1:200 Abcam plc, Cambridge, UK  
#ab14705 
 
Supplemental References:  
 
1. Goedert M, Spillantini MG, Jakes R, Rutherford D, & Crowther RA (1989) Multiple 
isoforms of human microtubule-associated protein tau: sequences and localization in 
neurofibrillary tangles of Alzheimer's disease. Neuron 3(4):519-526. 
2. Probst A, et al. (2000) Axonopathy and amyotrophy in mice transgenic for human 



















 We	collected	CSF	 from	AD	and	age	matched	control	patients,	and	 injected	 it	 into	young,	
pretangle	 stage	 P301S	 mice.	 As	 a	 result,	 we	 observed	 a	 local	 increase	 in	
hyperphosphorylated	tau	pathology	in	both	AD	and	control	CSF	treated	mice,	indicating	that	
human	CSF	tau	could	exhibit	prion-like	characteristics.	However,	more	patient	samples	will	






order	to	concentrate	 it	around	100	times	and	so	to	be	able	to	 inject	 it	 intracerebrally	 into	










mice.	 Initial,	 preliminatry	 quantification	 of	 tau	 pathology	 in	 the	 whole	 hippocampus	
comprising	 the	 injection	 site	 (-2	 to	 -3	 mm	 from	 Bregma)	 did	 not	 show	 any	 significant	
















of	 AT8	 pathology	 in	 the	 right	 CA3	 region	 of	 AD	 CSF	 treated	 mice,	 compared	 to	 their	




Figure	4.	Quantification	of	AT8	 tau	pathology	 in	 the	CA1,	CA3	and	DG	hippocampal	 subregions	at	 -2	 to	 -2.2	
from	Bregma	(A)	revealed	significantly	more	signal	in	the	CA3	of	the	injected	versus	non-injected	side,	in	both	
AD	(n=10)	and	control	(n=8)	CSF	seeded	mice.	The	results	are	depicted	using	a	heat	map	showing	differences	
between	 the	 injected	 and	 non-injected	 hippocampus	 (B)	 in	 AD	 (top	 image)	 and	 Control	 patients	 (bottom	
image),	 as	 color	 grade	 depicts	 p-values.	 Star	 indicates	 the	 injection	 site,	 *	 indicates	 p<0.05,	 **	 indicates	
p<0.001,	as	based	on	Student`s	t-test.	Error	bars	indicate	SEMs.	
	
However,	 even	 if	 total	 hippocampal	 AT8	 load	 was	 above	 the	 baseline	 observed	 in	 non-
treated	 injected	mice	 for	 both	 AD	 and	 Control	 patients	 (see	 Fig.	 S3	 in	 Skachokova	 et	 al.,	
2016),	we	did	not	find	any	significant	difference	between	those	3	groups.	Also,	we	observed	








from	 fully	 asymptomatic	 patients	 (e.g.	 patients’	 spouses).	 This	 could	be	 addressed	by	 the	
70	
	






























































































































































































































































































After	drying,	 sections	were	deparaffinised	by	placing	 them	 subsequently	 in	Xylol	 (20	min,	
















were	 then	 washed	 with	 H2O	 to	 stop	 the	 reaction	 and,	 in	 some	 cases,	 slides	 were	
counterstained	 with	 hematoxyline	 (J.T.	 Baker).	 Finally,	 sections	 were	 dehydrated	 in	 70%	
ethanol	 (1	min),	96%	EtOH	(2x1	min),	100%	EtOH	(2x1	min)	and	xylol,	and	mounted	using	







Species	 Antigen	 Concentration/Use	 Source	
82E1	
	
mouse	 Amyloid-β	 1:1000/	IHC	 Demeditec,	Germany	





mouse	 PHF	tau	(Ser212/Thr214)	 1:1000/	IHC	 Thermo	Scientific,	USA	
HT7	
	
mouse	 Human	tau159-163	 1:1000/	WB	 Pierce,	USA	
TauC3	
	
mouse	 Truncated	tau	(Asp421)	 1:1000/	IHC,	WB	 Santa	Cruz	Biotechnology,	USA	
MC1	 mouse	 tau5-15	and	tau312/322	 1:1000/	IHC	 P.	Davies,	Albert	Einstein	
College	of	Medicine,	NYC,	USA	
















rabbit	 Postsynaptic	vesicles	 1:1000/	IHC	 Synaptic	System,	Germany	




mouse	 Presynaptic	vesicles	 1:1000/	IHC	 Millipore,	USA	
β-actin	
	
mouse	 Actin	 1:5000/	WB	 Sigma-Aldrich,	USA	
Cox1a	
	


























































images	 were	 acquired	 using	 an	 A1	 confocal	 microscope	 (Nikon,	 USA).	 All	 images	 were	
acquired	at	the	same	exposure	and	were	automatically	aligned	using	the	stitching	tool	in	the	







Basel.	 The	 trial	was	approved	by	 the	 local	 Ethics	Commission	of	 the	Canton	of	Basel,	 and	
recruitment	 was	 limited	 to	 patients	 with	 a	 Mini	 Mental	 Score	 >19/30	 for	 reasons	 of	
informed	 consent	 (Pachet	 et	 al.	 2010).	 Subsequent	 patients	 examined	 for	 potential	
neurodegenerative	dementia	at	the	Memory	Clinic	were	included	in	the	study.	Up	to	15	ml	
of	 CSF	 per	 patient	 were	 collected	 by	 lumbar	 puncture	 after	 obtaining	 written	 informed	
consent	 of	 the	 patient	 and	 a	 care-giver.	 Final	 clinical	 diagnosis	was	 based	 on	multimodal	
assessments	including	neuropsychological	testing,	brain	MRI	imaging,	CSF	tau	and	Aβ	level	
measurements,	and,	in	selected	cases,	rbf-SPECT	imaging.		
For	 purpose	 of	 inoculation	 into	 mice,	 CSF	 samples	 derived	 from	 the	 patients	 with	 the	
highest	(“AD	CSF”	group,	n=5)	and	the	lowest	(“Control	CSF”	group,	n=4)	probability	of	AD-









control	 patients	was	 related	 to	 non-neurodegenerative	 causes	 (e.g.	 vascular	 dementia	 or	








in	 the	 small	 volumes	 that	 could	be	 injected	 into	mouse	brains,	 human	CSF	 samples	were	
concentrated.		To	this	end,	10	ml	of	human	CSF	per	patient	was	lyophilized	at	−80°	C,	0.01	
mbar	 vacuum	pressure,	overnight,	using	an	Alpha	2-4	 LSC	plus	 lyophilizer	 (Millrock,	USA).	
The	dried	product	was	reconstituted	 in	1	ml	sterile	H2O	and	dialyzed	 in	order	to	decrease	
salts	 content	 using	 Float-A-Lyzer®	 G2	 (Spectrum	 Labs,	 USA)	 during	 24h	 with	 3	 buffer	





















































8-bit	 images,	 hippocampus	 was	 selected	 as	 a	 region	 of	 interest,	 threshold	 was	 set	
automatically	 and	 the	 area	 and	mean	grey	 value	were	measured.	 In	order	 to	 analyse	 the	
effect	of	CSF	inoculation	on	Aβ-plaque-burden,	linear	mixed-effects	models	were	used.	We	
thereby	 compared	 the	 injected	 to	 the	 non-injected	 hippocampal	 side.	 Aβ-plaque	 burden	
served	as	dependent	variables,	independent	variables	were	hippocampal	sides	(injected	vs.	
non-injected).	 Subject	was	 treated	as	a	 random	 factor.	 Side	was	nested	within	 time	point	





For	 quantification	 of	 tau	 pathology,	 the	 number	 of	 AT8,	 AT100	 and	Gallyas	 positive	NFTs	
was	counted	using	the	Cell	counter	plugin	 in	 ImageJ.	Then	average	score	from	all	sections	
per	 animal	 and	 per	 group	 was	 made.	 For	 the	 AT8	 heatmap	 average	 tau	 pathology	 per	
Bregma	level	per	group	was	calculated	and	manually	colour	graded	using	the	Windows	Paint	
program.	 The	 amounts	 of	 granular	 tau	 pathology	 in	 3	 hippocampal	 regions	 (CA1,	 CA3,	
































































































































































































































































































































































































































List of abbreviations 
	
	
aa		
Aβ	
Aβ	40		
Aβ	42		
AD		
APP		
Asp		
C-terminal		
CAA		
CBD		
CSF	
DNA		
ECL		
g		
GA		
GSK3	
FTD		
H		
IHC		
IFL		
ISF		
kDa		
MAPK		
MAPT		
µm		
mm		
MCI		
MTBR		
N-terminal		
nm		
nmol		
NFTs		
PBS		
PCR		
PiD		
PSEN1	
PSP	
s		
Tau62	
tTs		
VAMP2	
	
	
	
amino	acids	
amyloid	beta	
amyloid	beta	40	
amyloid	beta	42	
Alzheimer’s	disease	
amyloid	precursor	protein	
aspartic	acid	
carboxy	terminal	
cerebral	amyloid	angiopathy		
corticobasal	degeneration		
cerebrospinal	fluid	
deoxyribonucleic	acid	
enhanced	chemiluminescence	
gram	
golgi	apparatus	
glycogen	synthase	kinase	3	
frontotemporal	dementia		
hour	
immunohistochemistry	
immunofluorescence	
interstitial	fluid	
kilo	daltons	
microtubule	associated	protein	kinase	
microtubule	associated	protein	tau	
micrometer(s)	
millimeter(s)	
mild	cognitive	impairment	
microtubule	binding	region	(of	tau)	
amino	terminal	
nanometer(s)	
nanomolar	
neurofibrillary	tangles	
phosphate	buffered	saline	
polymerase	chain	reaction	
Pick’s	disease	
presenelin	1	
progressive	supranuclear	palsy	
second(s)	
transgenic	mice	expressing	truncated	tau	
tetracycline	controlled	transcriptional	silencer	element	
vesicle	associated	membrane	protein	2	 	
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